Literature DB >> 24980189

Landmarks in non-muscle-invasive bladder cancer.

Laura S Mertens1, Yann Neuzillet2, Simon Horenblas1, Bas W G van Rhijn1.   

Abstract

Bladder cancer is divided into two entities: non-muscle-invasive (NMIBC) and muscle invasive bladder cancer. NMIBC represents 75% of primary diagnoses and is characterized by frequent recurrence but a low risk of mortality. Throughout urological history, significant progress in detection, diagnosis, and treatment of NMIBC has been made. However, bladder cancer remains a heterogeneous disease with varying pathology, molecular background, diagnostic options, and subsequent therapies for the individual patient. Although significant progress has been made over the years, the improvement of bladder cancer outcomes remains the goal of future research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24980189     DOI: 10.1038/nrurol.2014.130

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


  61 in total

1.  Infiltrating carcinoma of the bladder; relation of potential curability to depth of infiltration.

Authors:  H J JEWETT
Journal:  Trans Am Assoc Genitourin Surg       Date:  1945

Review 2.  The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials.

Authors:  Richard J Sylvester; Willem Oosterlinck; J Alfred Witjes
Journal:  Eur Urol       Date:  2008-01-15       Impact factor: 20.096

3.  Optical biopsy in human urologic tissue using optical coherence tomography.

Authors:  G J Tearney; M E Brezinski; J F Southern; B E Bouma; S A Boppart; J G Fujimoto
Journal:  J Urol       Date:  1997-05       Impact factor: 7.450

4.  Prognostic value of p53 for high risk superficial bladder cancer with long-term followup.

Authors:  P M J Moonen; B van Balken-Ory; L A L M Kiemeney; J A Schalken; J A Witjes
Journal:  J Urol       Date:  2007-01       Impact factor: 7.450

Review 5.  Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results.

Authors:  J Alfred Witjes; Kees Hendricksen
Journal:  Eur Urol       Date:  2007-08-20       Impact factor: 20.096

6.  Nonspecific immunotherapy with BCG vaccine in bladder tumors: a preliminary report.

Authors:  J A Martinez-Piñeiro; P Muntañola
Journal:  Eur Urol       Date:  1977       Impact factor: 20.096

7.  An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.

Authors:  Per-Uno Malmström; Richard J Sylvester; David E Crawford; Martin Friedrich; Susanne Krege; Erkki Rintala; Eduardo Solsona; Savino M Di Stasi; J Alfred Witjes
Journal:  Eur Urol       Date:  2009-04-24       Impact factor: 20.096

Review 8.  ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder.

Authors:  Maximilian Burger; Willem Oosterlinck; Badrinath Konety; Sam Chang; Sigurdur Gudjonsson; Raj Pruthi; Mark Soloway; Eduardo Solsona; Paul Sved; Marko Babjuk; Maurizio A Brausi; Christopher Cheng; Eva Comperat; Colin Dinney; Wolfgang Otto; Jay Shah; Joachim Thürof; J Alfred Witjes
Journal:  Eur Urol       Date:  2012-09-05       Impact factor: 20.096

9.  Mitomycin instillation to prevent recurrence of superficial bladder carcinoma. Results of a controlled, prospective study in 58 patients.

Authors:  H Huland; U Otto
Journal:  Eur Urol       Date:  1983       Impact factor: 20.096

10.  Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer.

Authors:  Kees Hendricksen; Wim P J Witjes; Jan G Idema; Jan J M Kums; Oncko B van Vierssen Trip; Marcel J F M de Bruin; Henk Vergunst; Christien T M Caris; Maria H D Janzing-Pastors; J Alfred Witjes
Journal:  Eur Urol       Date:  2007-12-27       Impact factor: 20.096

View more
  9 in total

1.  Dietary glycemic index, glycemic load and risk of bladder cancer: a prospective study.

Authors:  Xin Xu; Nitin Shivappa
Journal:  Eur J Nutr       Date:  2020-06-23       Impact factor: 5.614

2.  Correlation of ANXA1 expression with drug resistance and relapse in bladder cancer.

Authors:  Shuliang Yu; Qian Meng; Huihui Hu; Man Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

3.  Circular RNA expression is abundant and correlated to aggressiveness in early-stage bladder cancer.

Authors:  Lars Dyrskjøt; Jakob Skou Pedersen; Trine Line Hauge Okholm; Morten Muhlig Nielsen; Mark P Hamilton; Lise-Lotte Christensen; Søren Vang; Jakob Hedegaard; Thomas Birkballe Hansen; Jørgen Kjems
Journal:  NPJ Genom Med       Date:  2017-11-28       Impact factor: 8.617

4.  Proceedings of the 3rd Annual Albert Institute for Bladder Cancer Research Symposium.

Authors:  Thomas W Flaig; Ashish M Kamat; Donna Hansel; Molly A Ingersoll; H Barton Grossman; Cathy Mendelsohn; David DeGraff; Joseph C Liao; John A Taylor
Journal:  Bladder Cancer       Date:  2017-07-27

5.  Dominant role of CDKN2B/p15INK4B of 9p21.3 tumor suppressor hub in inhibition of cell-cycle and glycolysis.

Authors:  Yong Xia; Yan Liu; Chao Yang; Diane M Simeone; Tung-Tien Sun; David J DeGraff; Moon-Shong Tang; Yingkai Zhang; Xue-Ru Wu
Journal:  Nat Commun       Date:  2021-04-06       Impact factor: 14.919

Review 6.  Explainable artificial intelligence (XAI): closing the gap between image analysis and navigation in complex invasive diagnostic procedures.

Authors:  S O'Sullivan; M Janssen; Andreas Holzinger; Nathalie Nevejans; O Eminaga; C P Meyer; Arkadiusz Miernik
Journal:  World J Urol       Date:  2022-01-27       Impact factor: 3.661

7.  Contrast-Enhanced Ultrasound in the Bladder: Critical Features to Differentiate Occupied Lesions.

Authors:  Qiping Liu; Huiling Gong; Hui Zhu; Chunyan Yuan; Bin Hu
Journal:  Comput Math Methods Med       Date:  2021-10-12       Impact factor: 2.238

8.  Downregulation of DOCK1 sensitizes bladder cancer cells to cisplatin through preventing epithelial-mesenchymal transition.

Authors:  Da-Jin Chen; Wei Chen; Hong Jiang; Hao Yang; Yu-Cheng Wang; Jiang-Hua Chen
Journal:  Drug Des Devel Ther       Date:  2016-09-08       Impact factor: 4.162

9.  Comprehensive immune transcriptomic analysis in bladder cancer reveals subtype specific immune gene expression patterns of prognostic relevance.

Authors:  Runhan Ren; Kathrin Tyryshkin; Charles H Graham; Madhuri Koti; D Robert Siemens
Journal:  Oncotarget       Date:  2017-08-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.